Valerio Therapeutics Acquires Emglev Therapeutics

AbbVie Acquires Cerevel Therapeutics

December 6, 2023

Biotechnology

AbbVie Inc. acquired Cerevel Therapeutics for $45.00 per share, valuing Cerevel at approximately $8.7 billion, to bolster AbbVie's neuroscience pipeline. The deal adds Cerevel's clinical-stage assets—including emraclidine, tavapadon, CVL-354 and darigabat—and is intended to expand AbbVie's capabilities and commercial potential in psychiatric and neurological disorders.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Servier Acquires Symphogen A/S from Novo Holdings and Other Owners

April 3, 2020

Biotechnology

Servier has acquired 100% of the share capital of Symphogen A/S from Novo Holdings and the remaining owners, taking ownership of the Danish therapeutic antibody discovery and early biologics development company. The deal brings Symphogen’s antibody discovery platform and CMC biologics development capabilities into Servier’s oncology and immuno-oncology R&D efforts to strengthen its biologics pipeline and development capacity.

SERB Pharmaceuticals Acquires Y-mAbs Therapeutics

September 16, 2025

Biotechnology

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.